regn

Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan

[at noodls] – TARRYTOWN, N.Y., March 3, 2014 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application … moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to view […]

2:24 am Regeneron Pharms and Bayer HealthCare (BAYRY) announce regulatory submission of EYLEA injection for the treatment of diabetic macular edema in Japan

moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to view […]

No Looking Back for Regeneron’s Eylea

moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to view […]

Almost There: S&P 500 Gains, Still Down in 2014

moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to view […]

7:33 am Regeneron Pharms announces FDA acceptance of EYLEa injection supplemental biologics license application for the treatment of macular edema following branch retinal vein occlusion

moreView todays social media effects on REGNView the latest stocks trending across Twitter. Click to view dashboardSee who Regeneron is hiring next, click here to view […]